Indication
C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
2 clinical trials
4 products
Product
Sepantronium BromideClinical trial
A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell LymphomasStatus: Recruiting, Estimated PCD: 2025-03-01
Product
ACALABRUTINIBProduct
Lisocabtagene maraleucelProduct
Lymphodepleting chemotherapy